论文部分内容阅读
目的目的评价紫杉醇联合卡铂(TP)与单药紫杉醇(T)在早期Luminal B型乳腺癌新辅助化疗中的效果。方法回顾我院2013年1月~2016年3月收治的36例乳腺浸润性导管癌患者,临床分期II~III期,病理分级I I~I I I级、分子分型Luminal B型(ER或PR阳性,HER2阴性,Ki 67大于15%),所有患者均采用新辅助化疗,应用紫杉醇联合卡铂15例与单药紫杉醇21例,化疗评价采用Fisher分级方法分为p CR和非p CR。对比分析两种化疗方案效果。结果 TP组p CR率为26.67%,T组为9.52%,两组乳腺癌治疗疗效比较有差异(P<0.05)。结论临床II~III期,病理分级II~III级,Luminal B型乳腺癌,术前应用紫杉醇联合卡铂化疗效果良好,可达到较高p CR率,不良反应少,安全性高,可临床推广应用。
Objective To evaluate the efficacy of paclitaxel combined with carboplatin (TP) and single-agent paclitaxel (T) in neoadjuvant chemotherapy of early Luminal B breast cancer. Methods Thirty-six patients with invasive ductal carcinoma of the breast were enrolled in our hospital from January 2013 to March 2016. The clinical stage was stage II-III, the pathological grade was grade II-III, the molecular type Luminal B was positive (ER or PR, HER2 negative and Ki 67> 15%). All patients received neoadjuvant chemotherapy. Paclitaxel plus carboplatin was used in 15 patients and paclitaxel alone in 21 patients. Chemotherapy was divided into pCR and non-pCR by Fisher’s grading method. Compare the effects of two chemotherapy regimens. Results The p CR rate of TP group was 26.67%, while that of T group was 9.52%. There was significant difference between the two groups in breast cancer treatment (P <0.05). Conclusions The clinical effect of preoperative application of paclitaxel combined with carboplatin is good, with high pCR rate, fewer adverse reactions, high safety, and clinical promotion application.